Pfiz­er grabs a sol­id en­dorse­ment from FDA in­sid­ers for their knock­off of Am­gen’s flag­ship drug Epogen

Pfiz­er’s sec­ond at­tempt to win an FDA OK for Hos­pi­ra’s biosim­i­lar of Am­gen’s fast-de­clin­ing ane­mia drug, Epogen, is on course to a like­ly ap­proval — with few or no fire­works planned for an up­com­ing pan­el re­view.

Re­ject­ed by the FDA back in the ear­ly biosim­i­lar days of 2015, reg­u­la­tors start­ed off their re­view by giv­ing a clear nod to the sec­ond ef­fort, which comes af­ter the phar­ma gi­ant ac­quired Hos­pi­ra and its pipeline of knock­offs for $16 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.